Form 4: KalVista Pharmaceuticals' Chief Medical Officer Reports Stock Transactions
SEC Form 4
Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, reports the vesting and sale of shares to cover tax obligations.
Summary
- On May 17, 2024, Paul K. Audhya acquired 30,614 shares of Common Stock.
- On May 20, 2024, Audhya sold 13,175 shares of Common Stock at a weighted average price of $11.7645.
- These sales were to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs).
- Audhya also converted Restricted Stock Units and Performance Stock Units into common stock on May 20, 2024.
- Following these transactions, Audhya directly owns 70,325 shares of Common Stock.
- Audhya also holds 19,350 Restricted Stock Units, 24,167 Restricted Stock Units, and 24,167 Performance Stock Units.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are related to tax obligations from vesting equity, which is a normal occurrence. There is no indication of significant concern or excitement.
Positives
- The vesting of RSUs and PSUs indicates that performance metrics were likely achieved, which is a positive sign for the company.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.
Comparison to Industry Standards
- Monitoring insider transactions is a common practice in the financial industry to gauge the sentiment of company executives.
- Similar filings are made by executives at companies like Amgen, Biogen, and Vertex Pharmaceuticals, providing insights into their stock ownership and trading activities.
- These filings are publicly available and are used by analysts and investors to assess the financial health and future prospects of these companies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares, but it is primarily related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/17/2024 | Date of acquisition of Common Stock. |
| 05/20/2024 | Date of sale of Common Stock and conversion of RSUs and PSUs. |
| 05/21/2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.